Skip to main content

Advertisement

SpringerLink
Log in

Giant cell tumor of bone

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Giant cell tumor of bone is an enigmatic osseous neoplasm that is histologically benign but clinically shows local aggression and metastatic potential. The absence of clinical, radiographic, or pathologic features that are predictive of tumor behavior and patient outcome has resulted in recent attention to the pathobiology of giant cell tumor of bone. In this report, the clinicopathologic features of and current treatment approaches to giant cell tumor of bone are reviewed. Recent investigations of the specific role of the cell populations present in giant cell tumor of bone that influence tumor proliferation, bone resorption, and its clinical behavior are described.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gamberi G, Benassi MS, Bohling T, et al.: Prognostic relevance of C-myc gene expression in giant-cell tumor of bone. J Orthop Res 1998, 16:1–7.

    Article  PubMed  CAS  Google Scholar 

  2. Zheng MH, Fan Y, Panicker A, et al.: Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization. Am J Pathol 1995, 147:1559–1566. The authors present data that purports a predictive value to VEGF expression in giant cell tumor of bone supported by a correlation between the levels of VEGF expression and radiographic aggressiveness.

    PubMed  CAS  Google Scholar 

  3. Zheng MH, Xu J, Robbins P, et al.: Gene expression of vascular endothelial growth factor in giant cell tumors of bone. Hum Pathol 2000, 31:804–812.

    Article  PubMed  CAS  Google Scholar 

  4. Malawer MM, Bickels J, Meller I,et al.: Cryosurgery in the treatment of giant cell tumor: a long-term followup study. Clin Orthop 1999, 176–188.

  5. Turcotte RE, Wunder JS, Isler MH, et al.: Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop 2002, 248–258.

  6. Trieb K, Bitzan P, Lang S, et al.: Recurrence of curetted and bone-grafted giant-cell tumours with and without adjuvant phenol therapy. Eur J Surg Oncol 2001, 27:200–202.

    Article  PubMed  CAS  Google Scholar 

  7. Nicholson NC, Ramp WK, Kneisl JS, Kaysinger KK: Hydrogen peroxide inhibits giant cell tumor and osteoblast metabolism in vitro. Clin Orthop 1998, 250–260.

  8. Durr HR, Maier M, Jansson V, et al.: Phenol as an adjuvant for local control in the treatment of giant cell tumour of the bone. Eur J Surg Oncol 1999, 25:610–618.

    Article  PubMed  CAS  Google Scholar 

  9. Blackley HR, Wunder JS, Davis AM, et al.: Treatment of giant-cell tumors of long bones with curettage and bonegrafting. J Bone Joint Surg Am 1999, 81:811–820.

    Article  PubMed  CAS  Google Scholar 

  10. Malone S, O’Sullivan B, Catton C, et al.: Long-term follow-up of efficacy and safety of megavoltage radiotherapy in high-risk giant cell tumors of bone. Int J Radiat Oncol Biol Phys 1995, 33:689–694.

    Article  PubMed  CAS  Google Scholar 

  11. Miszczyk L, Wydmanski J, Spindel J: Efficacy of radiotherapy for giant cell tumor of bone: given either postoperatively or as sole treatment. Int J Radiat Oncol Biol Phys 2001, 49:1239–1242.

    Article  PubMed  CAS  Google Scholar 

  12. Nair MK, Jyothirmayi R: Radiation therapy in the treatment of giant cell tumor of bone. Int J Radiat Oncol Biol Phys 1999, 43:1065–1069.

    Article  PubMed  CAS  Google Scholar 

  13. Chakravarti A, Spiro IJ, Hug EB, et al.: Megavoltage radiation therapy for axial and inoperable giant-cell tumor of bone. J Bone Joint Surg Am 1999, 81:1566–1573.

    PubMed  CAS  Google Scholar 

  14. Fidler MW: Surgical treatment of giant cell tumours of the thoracic and lumbar spine: report of nine patients. Eur Spine J 2001, 10:69–77.

    Article  PubMed  CAS  Google Scholar 

  15. Lin PP, Guzel VB, Moura MF, et al.: Long term follow-up of giant cell tumor of the sacrum treated with selective arterial embolization. Cancer 2002, 95:1317–1325.

    Article  PubMed  Google Scholar 

  16. Singh RK, Gutman M, Bucana CD, et al.: Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A 1995, 92:4562–4566.

    Article  PubMed  CAS  Google Scholar 

  17. Strander H, Boethius J, Erhardt K, et al.: Does successful interferon treatment of tumor patients require life-long treatment? J Interferon Res 1987, 7:619–626.

    PubMed  CAS  Google Scholar 

  18. Kaiser U, Neumann K, Havemann K: Generalised giant-cell tumour of bone: successful treatment of pulmonary metastases with interferon alpha, a case report. J Cancer Res Clin Oncol 1993, 119:301–303.

    Article  PubMed  CAS  Google Scholar 

  19. Kaban LB, Mulliken JB, Ezekowitz RA, et al.: Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics 1999, 103:1145–1149.

    Article  PubMed  CAS  Google Scholar 

  20. Zheng MH, Siu P, Papadimitriou JM, et al.: Telomeric fusion is a major cytogenetic aberration of giant cell tumors of bone. Pathology 1999, 31:373–378.

    Article  PubMed  CAS  Google Scholar 

  21. Sciot R, Dorfman H, Brys P, et al.: Cytogenetic-morphologic correlations in aneurysmal bone cyst, giant cell tumor of bone and combined lesions: a report from the CHAMP study group. Mod Pathol 2000, 13:1206–1210.

    Article  PubMed  CAS  Google Scholar 

  22. Atkins GJ, Haynes DR, Graves SE, et al.: Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res 2000, 15:640–649. The authors provide data demonstrating that the stromal cells of giant cell tumors of bone express the necessary signals to promote and support osteoclastogeneis and osteoclast-mediated osteolysis.

    Article  PubMed  CAS  Google Scholar 

  23. Miyamoto N, Higuchi Y, Tajima M, et al.: Spindle-shaped cells derived from giant-cell tumor of bone support differentiation of blood monocytes to osteoclast-like cells. J Orthop Res 2000, 18:647–654.

    Article  PubMed  CAS  Google Scholar 

  24. Huang L, Xu J, Wood DJ, Zheng MH: Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol 2000, 156:761–767.

    PubMed  CAS  Google Scholar 

  25. Yasuda H, Shima N, Nakagawa N, et al.: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesisinhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998, 95:3597–3602.

    Article  PubMed  CAS  Google Scholar 

  26. Lacey DL, Timms E, Tan HL, et al.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165–176.

    Article  PubMed  CAS  Google Scholar 

  27. Anderson DM, Maraskovsky E, Billingsley WL, et al.: A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997, 390:175–179.

    Article  PubMed  CAS  Google Scholar 

  28. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ: TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998, 188:997–1001.

    Article  PubMed  CAS  Google Scholar 

  29. Tsuda E, Goto M, Mochizuki S, et al.: Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997, 234:137–142.

    Article  PubMed  CAS  Google Scholar 

  30. Roux S, Amazit L, Meduri G, et al.: RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J Clin Pathol 2002, 117:210–216.

    Article  PubMed  CAS  Google Scholar 

  31. Huang L, Xu J, Kumta SM, Zheng MH: Gene expression of glucocorticoid receptor alpha and beta in giant cell tumour of bone: evidence of glucocorticoid-stimulated osteoclastogenesis by stromal-like tumour cells. Mol Cell Endocrinol 2001, 181:199–206.

    Article  PubMed  CAS  Google Scholar 

  32. Atkins GJ, Bouralexis S, Haynes DR, et al.: Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone 2001, 28:370–377.

    Article  PubMed  CAS  Google Scholar 

  33. Dodds RA, James IE, Rieman D, et al.: Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption. J Bone Miner Res 2001, 16:478–486.

    Article  PubMed  CAS  Google Scholar 

  34. Rao VH, Singh RK, Delimont DC, et al.: Transcriptional regulation of MMP-9 expression in stromal cells of human giant cell tumor of bone by tumor necrosis factor-alpha. Int J Oncol 1999, 14:291–300.

    PubMed  CAS  Google Scholar 

  35. Rao VH, Singh RK, Delimont DC, et al.: Interleukin-1beta upregulates MMP-9 expression in stromal cells of human giant cell tumor of bone. J Interferon Cytokine Res 1999, 19:1207–1217.

    Article  PubMed  CAS  Google Scholar 

  36. Zheng MH, Robbins P, Xu J, et al.: The histogenesis of giant cell tumour of bone: a model of interaction between neoplastic cells and osteoclasts. Histol Histopathol 2001, 16:297–307. This review provides an excellent update on a working model of the histogenesis and pathobiology of giant cell tumor of bone.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Orthopedic Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 444, 77030, Houston, TX, USA

    Alan W. Yasko MD

Authors
  1. Alan W. Yasko MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yasko, A.W. Giant cell tumor of bone. Curr Oncol Rep 4, 520–526 (2002). https://doi.org/10.1007/s11912-002-0067-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-002-0067-2

Keywords

Search

Navigation